Agressiveness and agitation of acute psychotic patients: influence in safety and effectiveness of risperidone treatment.

Trial Profile

Agressiveness and agitation of acute psychotic patients: influence in safety and effectiveness of risperidone treatment.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 May 2011

At a glance

  • Drugs Risperidone (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 10 Mar 2011 Actual initiation date (Nov 2001) added as reported by ClinicalTrials.gov.
    • 10 Mar 2011 Actual end date (August 2002) added as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Planned number of patients changed from 1250 to 1882 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top